Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMariam NawasMDMichael W. DrazerRLRichard A. Larson

Discussion

Loading...

Member takes

Overview

Phase 1b trial evaluates safety and efficacy of ruxolitinib with ivosidenib, suggesting improved outcomes in IDH1-mutated myeloproliferative neoplasms.

Key Points

  • To determine the safety and maximum tolerated dose of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms (MPNs).
  • Initiated phase 1b trial targeting IDH1-mutated Ph- MPN or MDS/MPN overlap syndrome.
  • Utilized Rolling 6 design for dose escalation/de-escalation of ivosidenib and ruxolitinib.
  • Primary endpoint focused on establishing maximum tolerated dose (MTD) of the drug combination.
  • Aimed for total enrollment of 18 patients to assess dose safety and efficacy.
  • Investigated overall survival and overall response rates in patients.
  • Exploratory endpoints include analysis of clonal dynamics and measurable residual disease via next generation sequencing.

Cite This Study

Nawas et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df97https://doi.org/10.1182/blood-2025-5608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations
  2. 2PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy2025
  3. 3Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome2024 · 50 citations
  4. 4Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations2025 · 5 citations
  5. 5A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia2025 · 2 citations